Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor β1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression

Clinical Cancer Research

Volumn 10, Issue 6, 2004, Pages 1992-1999

  Shariat, Shahrokh F ^a,b   Kattan, Michael W ^c   Traxel, Erica ^a   Andrews, Ben ^a   Zhu, Kuichun ^a   Wheeler, Thomas M ^a   Slawin, Kevin M ^a,d  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PROSTATE SPECIFIC ANTIGEN; SOLUBLE INTERLEUKIN 6 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER GROWTH; CANCER INVASION; GLEASON SCORE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OCCULT METASTASIS; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; SEMINAL VESICLE; TUMOR VOLUME;

DNA, NEOPLASM; HUMANS; INTERLEUKIN-6; LYMPHATIC METASTASIS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PLOIDIES; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PROSTATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-6; REGRESSION ANALYSIS; SEMINAL VESICLES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 1642392553     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0768-03     Document Type: Article

References (42)

1. Kattan MW, Stapleton AM, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer (Phila.) 1997;79:528-37.
2. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst (Bethesda) 1998; 90:766-71.
3. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-507.
4. Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001;58:393-9.
5. Partin AW, Kattan MW, Subong EN, et al. Combination of prostatespecific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update [see comments] [published erratum appears in J Am Med Assoc 1997; 278(2):118]. J Am Med Assoc 1997;277:1445-51.
6. Partin AW, Kattan MW, Subong EN, et al. Combination of prostatespecific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update [see comments] [published erratum appears in J Am Med Assoc 1997; 278(2):118]. J Am Med Assoc 1997;277:1445-51.
7. Pisansky TM, Blute ML, Suman VJ, Bostwick DG, Earle JD, Zincke H. Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens. Int J Radiat Oncol Biol Phys 1996;36:585-91.
8. D'Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000;18:1164-72.
9. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc 1998;280:969-74.
10. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. J Am Med Assoc 1999;281:1598-604.
11. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer (Phila.) 1997;79: 1370-80.
12. Stamey TA. Preoperative serum prostate-specific antigen (PSA) below 10 μg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. Clin Chem 2001;47:631-4.
13. Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with postradical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol 2002;167:103-11.
14. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Preoperative serum prostate-specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. J Urol 2000;164:1596-600.
15. Shariat SF, Lamb DJ, Kattan MW, et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 2002;20:833-41.
16. Shariat SF, Gottenger E, Nguyen C, et al. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res 2002;62:5974-9.
17. 1) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001;19:2856-64.
18. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001;58: 1008-15.
19. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182-7.
20. Kakehi K, Oka H, Mitsumori K, Itoh N, Ogawa O, Yoshida O. Elevation of serum transforming growth factor-1 level in patients with metastatic prostate cancer. Urol Oncol 1996;2:131-5.
21. Wheeler TM, Lebovitz RM. Fresh tissue harvest for research from prostatectomy specimens. Prostate 1994;25:274-9.
22. Greene DR, Wheeler TM, Egawa S, Dunn JK, Scardino PT. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol 1991;146:1069-76.
23. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer (Phila.) 1993;71:2031-40.
24. Kattan MW, Fearn PA, Leibel S, Potters L. The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2000;48:1469-74.
25. Leventis AK, Shariat SF, Kattan MW, Butler EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001;19:1030-9.
26. Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor β1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995;222:155-62.
27. Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor β1 level before radiotherapy correlates with long-term outcome of patients with lung carcinoma. Cancer (Phila.) 1999;86:1712-9.
28. Tsushima H, Ito N, Tamura S, et al. Circulating transforming growth factor β 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res 2001;7:1258-62.
29. Galizia G, Orditura M, Romano C, et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 2002;102:169-78.
30. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998;16:249-84.
31. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-56.
32. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334(Pt 2):297-314.
33. Hobisch A, Rogatsch H, Hittmair A, et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000;191:239-44.
34. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001;159:2159-65.
35. Mullberg J, Oberthur W, Lottspeich F, et al. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol 1994;152:4958-68.
36. Oh JW, Revel M, Chebath JA. Soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA. Cytokine 1996;8:401-9.
37. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993;90:11924-8.
38. Peters M, Muller AM, Rose-John S. Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood 1998;92:3495-504.
39. 2 stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem Biophys Res Commun 2002;290:249-55.
40. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy [see comments]. J Am Med Assoc 1999;281:1591-7.
41. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke, H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76:576-81.
42. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20:286-92.